TGTX

Analyst Note: TG Therapeutics, Inc. (TGTX)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

Classification: CONFIRMED-ACTIVE

• Conservative Entry: $46.62
• Current Price: $53.22
• Extension: +14.2% above conservative entry
• Breakout Level: The structure confirms a breakout has occurred, establishing the current price action as a confirmed active coil.

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Neuro / CNS (Tier Direct, High Confidence) Thesis Context: TGTX is a direct beneficiary of the secular shift toward novel, high-efficacy therapies for Multiple Sclerosis (MS). The company operates at the intersection of commercial-stage execution and the expanding addressable market for subcutaneous (SC) administration in the CNS space.

While the primary exposure is to the Neuro/CNS therapeutic wave, the setup also reflects the broader "Biotech" secular theme where commercial-stage companies with clear revenue inflection points are re-rating. The "Tier Direct" classification indicates that TGTX's core value driver (BRIUMVI) is the primary vehicle for this thesis, rather than a peripheral exposure. The transition from IV to SC administration represents a structural expansion of the total addressable market (TAM) within the anti-CD20 class, capturing the 35% of the market currently served by patient-administered segments.

3. Business Overview

Company Profile: TG Therapeutics is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Headquartered in New York City, the company has advanced from clinical-stage to commercial execution.

Core Product & Commercial Status:

• BRIUMVI (ublituximab-xiiy): Approved by the FDA in December 2022 for relapsing forms of MS (RMS). As of the latest reporting, the drug is commercially available in the U.S. and several international markets (including the EU since February 2024).
• Revenue Performance: Management reported Q1 2026 U.S. BRIUMVI net product revenue of approximately $195 million, exceeding the guidance range of $185–$190 million.
• Guidance: In the May 6, 2026 earnings call, management raised full-year U.S. revenue guidance to $885–$900 million and total global revenue guidance to approximately $925 million. Q2 guidance targets approximately $220 million in U.S. BRIUMVI net revenue.
• Adoption Metrics: More than 25,000 patients have been prescribed BRIUMVI globally. Management expects to reach a $1 billion annualized run rate before year-end 2026.

Pipeline & Future Catalysts:

• Subcutaneous BRIUMVI: Enrollment for the Phase 3 pivotal program evaluating the SC formulation was completed in April 2026. Management expects top-line data in the coming weeks (as of May 2026) and targets a potential 2028 launch, assuming positive outcomes and regulatory approval. This addresses the 35% of the anti-CD20 market currently served by SC therapies.
• IV Consolidation: The Phase 3 ENHANCE trial evaluating a consolidated day 1 and day 15 dosing schedule for IV BRIUMVI was completed in October 2025.
• Other Assets: The portfolio includes Cosibelimab (PD-L1 inhibitor), TG-1801 (CD47/CD19 bispecific), and azer-cel (Phase 1 for progressive MS, first patient dosed August 2025).

4. Archetype and Conviction

Archetype: Growth Leader Rationale: TGTX fits the "Growth Leader" archetype due to its transition from a clinical-stage biotech to a commercial entity delivering accelerating revenue, profitability, and clear path to $1B+ annualized run rate. The company is not a deep value recovery or a cyclical play; it is a compounder executing on a clear commercial ramp.

Valuation & Financial Spine:

• Forward Consensus: FY1 EPS of $1.38; FY2 EPS of $2.53.
• Profitability: Management noted the company has recently achieved profitability, though historical operating losses remain a factor to monitor.
• Conviction Stack:
• Thesis Strength: High. Direct exposure to a large, growing MS market with a differentiated SC product.
• Evidence Quality: Strong. Multiple primary sources (earnings transcripts, SEC filings) confirm enrollment completion, revenue beats, and raised guidance.
• Structural Quality: High. The ATR at breakout (4.4%) and current ATR (4.3%) indicate robust volatility consistent with a confirmed breakout in a high-growth sector.
• Rerating Potential: Significant. The market is currently pricing in the IV franchise; the SC launch (2028) and the consolidation of dosing schedules offer multiple expansion opportunities.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Clinical Failure: Negative top-line data from the Phase 3 SC BRIUMVI trial (expected "in the coming weeks" as of May 2026) would fundamentally alter the growth thesis.
• Commercial Disruption: A significant miss in Q2 guidance or a sharp decline in patient adoption rates (e.g., below 25,000 global patients) would weaken the commercial narrative.

Strengtheners:

• Positive SC Data: Confirmation of positive top-line data for the SC formulation would validate the 2028 launch timeline and expand the TAM.
• Guidance Raises: Further upward revisions to full-year or long-term revenue guidance.
• New Indications: Expansion of BRIUMVI into new MS indications or other B-cell diseases.

Evidence Gaps:

• Long-term Margin Trajectory: While profitability is noted as "recently achieved," specific details on the sustainability of operating margins beyond the current fiscal year are not explicitly detailed in the provided evidence.
• International Commercialization Scale: While EU availability is noted, specific revenue contributions from non-U.S. markets are not quantified in the provided snippets beyond the global total.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: High Key risks: 1) Potential negative top-line data from the Phase 3 SC trial; 2) Execution risk in achieving the $1B run rate target; 3) Regulatory delays for the SC formulation launch. Expected path: Management expects to reach $1B annualized run rate before year-end 2026, followed by the potential 2028 launch of the SC formulation, which should drive a second leg of growth as the company captures the patient-administered segment. Expected horizon: 12 to 24 months for the SC data readout and subsequent regulatory pathway to play out.